@article{c5f344c0a119422fa2752c36d01606b0,
title = "Low-Density Lipoprotein Cholesterol: Is 160 the New 190?",
keywords = "Editorials, LDL cholesterol, cardiovascular diseases",
author = "Virani, {Salim S.} and Ballantyne, {Christie M.}",
note = "Funding Information: Dr Virani received honoraria from the American College of Cardiology (Associate Editor for Innovations, acc.org) and the National Lipid Association, and is on the steering committee for the Patient and Provider Assessment of Lipid Management Registry at the Duke Clinical Research Institute (no financial remuneration). Dr Ballantyne received grant/research support (all paid to the institution, not the individual) from Amgen, Esperion, Regeneron, and Sanofi-Synthelabo; and is a consultant for Amgen, Esperion, Merck, Regeneron, and Sanofi-Synthelabo. Funding Information: This work was supported by a Department of Veterans Affairs Health Services Research & Development Service Investigator-Initiated grant (IIR 16–072), American Heart Association Beginning Grant-in-Aid (14BGIA20460366), American Diabetes Association Clinical Science and Epidemiology award (1-14-CE-44), Houston VA Health Services Research & Development Center for Innovations grant (HFP 90-020), and National Institutes of Health grant (R01-HL134320).",
year = "2018",
month = nov,
day = "20",
doi = "10.1161/CIRCULATIONAHA.118.034922",
language = "English",
volume = "138",
pages = "2326--2329",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "21",
}
